The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Adjuvant system AS01: helping to overcome the challenges of modern vaccines
Open accessAbstract
Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by enhancing antigen presentation to antigen-specific immune cells with the aim to confer long-term protection against targeted pathogens. Adjuvants have been used in vaccines for more than 90 years. Combinations of immunostimulatory molecules, such as in the Adjuvant System AS01, have opened the way to the development of new or improved vaccines.Areas covered: AS01 is a liposome-based vaccine adjuvant system containing two immunostimulants: 3-O-desacyl-4ʹ-monophosphoryl lipid A (MPL) and the saponin QS-21. Here we describe studies investigating the mode of action of AS01, and consider the role of AS01 in enhancing specific immune responses to the antigen for selected candidate vaccines targeting malaria and herpes zoster. The effects of AS01 are rapid and transient, being localized to the injected muscle and draining lymph node. AS01 is efficient at promoting CD4+ T cell-mediated immune responses and is an appropriate candidate adjuvant for inclusion in vaccines targeting viruses or intracellular pathogens.Expert commentary: AS01 activity to enhance adaptive responses depends on synergistic activities of QS-21 and MPL. AS01 adjuvantation shows good prospects for use in new vaccines targeted to populations with challenging immune statuses and against diseases caused by complex pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Systematic review of incidence and complications of herpes zoster: towards a global perspective
Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004833 · Cited by 938
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887 · cited 1×
“The first adjuvant used in human vaccines was aluminum salt, which has been included in vaccines since the 1920s to increase the magnitude of the antibody response [1].”
BackgroundDidierlaurent, A. M., Morel, S., Lockman, L., Giannini, S. L., Bisteau, M., Carlsen, H., Kielland, A., Vosters, O., Vanderheyde, N., Schiavetti, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901474 · Cited by 758
Self-citationA Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
The RTS, S. C. T. P. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208394 · Cited by 752
Mechanisms of Action of Adjuvants
Awate, S., Babiuk, L. A., & Mutwiri, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00114 · Cited by 732
Vaccine Adjuvants: from 1920 to 2015 and Beyond
Pasquale, A., Preiss, S., Silva, F., & Garçon, N. (2015) · Vaccines · doi:10.3390/vaccines3020320 · Cited by 648
Self-citationBache, E. B., Agnandji, S. T., Lell, B., Fernandes, J. F., Abossolo, B. P., Kabwende, A. L., Adégnika, A. A., Mordmüller, B. G., Kremsner, P. G., Loembé, M. M., et al. (2015) · The Lancet · doi:10.15496/publikation-6508 · Cited by 642
Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant
Casella, C. R., & Mitchell, T. C. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8228-6 · Cited by 560
Kester, K. E., Cummings, J. F., Ofori‐Anyinam, O., Ockenhouse, C. F., Krzych, U., Moris, P., Schwenk, R., Nielsen, R. A., Debebe, Z., Pinelis, E., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/600120 · Cited by 524
The mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives
Garçon, N., Chomez, P., & Van Mechelen, M. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.5.723 · Cited by 476
Self-citationMorel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., & Carlsen, H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.011 · Cited by 476
Self-citationThe RTS, S. C. T. P. (. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001685 · Cited by 474
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Groom, J. R., Richmond, J., Murooka, T. T., Sorensen, E. W., Sung, J. H., Bankert, K., von Andrian, U. H., Moon, J. J., Mempel, T. R., & Luster, A. D. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.016 · Cited by 433
Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems
Garçon, N., & Van Mechelen, M. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.29 · Cited by 314
Self-citationVaccine adjuvants: Current challenges and future approaches
Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J., & Narasimhan, B. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21523 · Cited by 296
Immune Responses to Varicella-Zoster in the Aged
Burke, B. L. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.1982.00340150091017 · Cited by 295
Didierlaurent, A. M., Collignon, C., Bourguignon, P., Wouters, S., Fierens, K., Fochesato, M., Dendouga, N., Langlet, C., Malissen, B., Lambrecht, B. N., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400948 · Cited by 266 · cited 2×
“Concentrations of cytokines in muscle and draining lymph node after injection with AS01 and gE antigen (data from [34]).”
BackgroundSelf-citationBaldridge, J. R., McGowan, P., Evans, J. T., Cluff, C., Mossman, S., Johnson, D., & Persing, D. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1129 · Cited by 256
Penny, M. A., Verity, R., Bever, C. A., Sauboin, C., Galactionova, K., Flasche, S., White, M. T., Wenger, E. A., Van de Velde, N., Pemberton-Ross, P., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00725-4 · Cited by 235
Vandepapelière, P., Horsmans, Y., Moris, P., Van Mechelen, M., Janssens, M., Koutsoukos, M., Van Belle, P., Clement, F., Hanon, E., Wettendorff, M., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.038 · Cited by 218
Self-citationBerkowitz, E. M., Moyle, G., Stellbrink, H.-J., Schürmann, D., Kegg, S., Stoll, M., El Idrissi, M., Oostvogels, L., Heineman, T. C., for the Zoster-015 HZ/su Study Group, et al. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu606 · Cited by 218
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants
Marty-Roix, R., Vladimer, G. I., Pouliot, K., Weng, D., Buglione-Corbett, R., West, K., MacMicking, J. D., Chee, J. D., Wang, S., Lu, S., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.683011 · Cited by 204
Stadtmauer, E. A., Sullivan, K. M., Marty, F. M., Dadwal, S. S., Papanicolaou, G. A., Shea, T. C., Mossad, S. B., Andreadis, C., Young, J.-A. H., Buadi, F. K., et al. (2014) · Blood · doi:10.1182/blood-2014-04-573048 · Cited by 179
Humoral and Cellular Immunity to Varicella‐Zoster Virus: An Overview
Arvin, A. M. (2008) · The Journal of Infectious Diseases · doi:10.1086/522123 · Cited by 178
Antigenic Diversity and Immune Evasion by Malaria Parasites
Ferreira, M. U., Nunes, M. D. S., & Wunderlich, G. (2004) · Clinical and Vaccine Immunology · doi:10.1128/cdli.11.6.987-995.2004 · Cited by 176
Asante, K. P., Abdulla, S., Agnandji, S. T., Lyimo, J., Vekemans, J., Soulanoudjingar, S., Owusu, R., Shomari, M., Leach, A. J., Jongert, E., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70100-1 · Cited by 175
Age-related changes in immunity: implications for vaccination in the elderly
Kovaiou, R. D., Herndler-Brandstetter, D., & Grubeck-Loebenstein, B. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000221 · Cited by 161
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
Penn‐Nicholson, A., Geldenhuys, H. D., Burny, W., der Most, R. G. V., Day, C. L., Jongert, E., Moris, P., Hatherill, M., Ofori‐Anyinam, O., Hanekom, W. A., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.05.088 · Cited by 155
Dendouga, N., Fochesato, M., Lockman, L., Mossman, S. P., & Giannini, S. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.088 · Cited by 149
Leroux-Roels, I., Leroux-Roels, G., Clement, F., Vandepapelière, P., Vassilev, V., Ledent, E., & Heineman, T. C. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis497 · Cited by 147
Immune senescence and vaccines to prevent herpes zoster in older persons
Levin, M. J. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.06.002 · Cited by 118
ISCOMATRIX vaccines mediate CD8+ T‐cell cross‐priming by a MyD88‐dependent signaling pathway
Wilson, N. S., Yang, B., Morelli, A. B., Koernig, S., Yang, A., Loeser, S., Airey, D., Provan, L., Hass, P., Braley, H., et al. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.71 · Cited by 102
Olotu, A., Moris, P., Mwacharo, J. K., Vekemans, J., Kimani, D., Janssens, M., Kai, O. K., Jongert, E., Lievens, M., Leach, A. J., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025786 · Cited by 98
Kashala, O., Amador, R., Valero-Bernal, M. V., Moreno, A., Barbosa, A., Nickel, B., Daubenberger, C., Guzmán, F., Pluschke, G., & Patarroyo, M. E. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00115-9 · Cited by 91
Mettens, P., Dubois, P. M., Demoitié, M., Bayat, B., Donner, M.-N., Bourguignon, P., Stewart, V. A., Heppner, D. G., Garçon, N., & Cohen, J. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.12.018 · Cited by 81
Self-citationAnsong, D., Asante, K. P., Vekemans, J., Owusu, S. K., Owusu, R., Brobby, N. W., Dosoo, D., Osei‐Akoto, A., Osei-Kwakye, K., Asafo‐Adjei, E., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018891 · Cited by 70
Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines
Leroux-Roels, G. G., Leroux‐Roels, I., Clément, F., Ofori‐Anyinam, O., Lievens, M., Jongert, E., Moris, P., Ballou, W. R., & Cohen, J. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29375 · Cited by 66
A systematic review and meta-analysis on the safety of newly adjuvanted vaccines among children
Stassijns, J., Bollaerts, K., Baay, M. F. D., & Verstraeten, T. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.12.024 · Cited by 64
Beck, Z., Matyas, G. R., & Alving, C. R. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.12.005 · Cited by 63
Fochesato, M., Dendouga, N., & Boxus, M. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1154247 · Cited by 35
Pooled analysis of safety data from pediatric Phase II RTS,S/AS malaria candidate vaccine trials
Vekemans, J., Guerra, Y., Lievens, M., Benns, S., Lapierre, D., Leach, A. J., & Verstraeten, T. (2011) · Human Vaccines · doi:10.4161/hv.7.12.18046 · Cited by 16
Tissue signatures influence the activation of intrahepatic CD8+ T cells against malaria sporozoites
Morrot, A., & Rodrigues, M. M. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00440 · Cited by 12
Cited by
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Vaccine adjuvants: mechanisms and platforms
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01557-7 · Cited by 1,020
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Del Giudice, G., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 610
Self-citationToward Nanotechnology-Enabled Approaches against the COVID-19 Pandemic
Weiss, C., Carriere, M., Fusco, L., Capua, I., Regla-Nava, J. A., Pasquali, M., Scott, J. A., Vitale, F., Unal, M. A., Mattevi, C., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c03697 · Cited by 601
Immunosenescence and human vaccine immune responses
Crooke, S. N., Ovsyannikova, I. G., Poland, G. A., & Kennedy, R. B. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0164-9 · Cited by 530
Metadata
- Authors
- Didierlaurent, A. M., Laupèze, B., Di Pasquale, A., Hergli, N., Collignon, C., & Garçon, N.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2016-08-02
- Volume
- 16
- Issue
- 1
- Pages
- 55-63
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2482786872
- Cited by
- 516
- References
- 49
- FWCI
- 16.82
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.